bendamustine accord 25 mg/ml sol. perf. (à diluer) i.v. flac.
accord healthcare b.v. - chlorhydrate de bendamustine monohydraté 26,14 mg/ml - eq. chlorhydrate de bendamustine 25 mg/ml - solution à diluer pour perfusion - 25 mg/ml - chlorhydrate de bendamustine monohydraté 26.14 mg/ml - bendamustine
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - le myélome multiple - agents antinéoplasiques - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
plerixafor accord
accord healthcare s.l.u. - plérixafor - multiple myeloma; hematopoietic stem cell transplantation - les immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.
granocyte 33,6 poudre et solvant pour solution injectable granocyte 33,6 poudre et solvant pour solution injectable
sanofi-aventis (suisse) sa - lenograstimum adnr - granocyte 33,6 poudre et solvant pour solution injectable - praeparatio cryodesiccata: lenograstimum adnr 263 µg corresp. 33.6 mio u.i., mannitolum, polysorbatum 20, natrii chloridum, argininum, phenylalaninum, methioninum, pro vitro. solvens: aqua ad iniectabile 1 ml. - neutropénie - biotechnologika
granocyte 13,4 poudre et solvant pour solution injectable
sanofi-aventis (suisse) sa - lenograstimum adnr - poudre et solvant pour solution injectable - praeparatio cryodesiccata: lenograstimum adnr 105 µg corresp. 13.4 mio u.i., mannitolum, polysorbatum 20, natrii chloridum, argininum, phenylalaninum, methioninum, pro vitro. solvens: aqua ad iniectabile 1 ml. - neutropénie - biotechnologika
ametycine 10 mg, poudre pour solution injectable
kyowa kirin holdings b.v. - mitomycine c 10 mg - poudre - 10 mg - pour un flacon > mitomycine c 10 mg - autre antibiotique cytotoxique - classe pharmacothérapeutique : autre antibiotique cytotoxique, code atc : l01dc03 (l : antinéoplasiques et immunomodulateurs).ce médicament empêche la multiplication de certaines cellules.